Skip to content

Technology that sends blood sugar-level updates to their smartphones improves outcomes for young people with type 1 diabetes, a Stanford trial shows.

Technology that sends blood sugar-level updates to their smartphones improves outcomes for young people with type 1 diabetes, a Stanford trial shows.

Published on

Stanford University bioengineers are developing a faster-acting formulation of insulin that can help diabetes patients better regulate their blood sugar levels.

Stanford University bioengineers are developing a faster-acting formulation of insulin that can help diabetes patients better regulate their blood sugar levels.

Stanford scientists have built a detailed picture of the biological clock of pregnancy, tracking thousands of metabolic markers throughout gestation.

Stanford scientists have built a detailed picture of the biological clock of pregnancy, tracking thousands of metabolic markers throughout gestation.

A Stanford team is developing a bioscaffold that helps insulin-producing cells get enough oxygen when transplanted for diabetes treatment.

A Stanford team is developing a bioscaffold that helps insulin-producing cells get enough oxygen when transplanted for diabetes treatment.

Taking a community-based approach to diabetes could help curb high rates of the disease in less wealthy nations, new research suggests.

Taking a community-based approach to diabetes could help curb high rates of the disease in less wealthy nations, new research suggests.

The latest type 1 diabetes technology improves the stability of patients' blood sugar levels throughout the day and during sleep, according to a new trial.

The latest type 1 diabetes technology improves the stability of patients' blood sugar levels throughout the day and during sleep, according to a new trial.

Published on

Results from a multi-center clinical trial show that a drug lowers the risk of kidney failure by a third in people with Type 2 diabetes and kidney disease.

Results from a multi-center clinical trial show that a drug lowers the risk of kidney failure by a third in people with Type 2 diabetes and kidney disease.

Type 1 diabetes starts out as a sneak attack by bad-actor antibodies. But scientists at Stanford and UCSF have developed an early-warning system.

Type 1 diabetes starts out as a sneak attack by bad-actor antibodies. But scientists at Stanford and UCSF have developed an early-warning system.

Published on

By delivering a drug directly to beta cells, researchers may be able to spur insulin production and potentially develop a diabetes therapy in the future.

By delivering a drug directly to beta cells, researchers may be able to spur insulin production and potentially develop a diabetes therapy in the future.

Published on

Although pioneering scientist Gerald Reaven thought that insulin resistance did not affect the kidney, new research suggests that the story is more complex.

Although pioneering scientist Gerald Reaven thought that insulin resistance did not affect the kidney, new research suggests that the story is more complex.

Published on